Tag:
Thelin
Latest Headlines
Latest Headlines
Pfizer halts Phase III trial, withdraws Thelin
Pfizer ( $PFE ) announced that it is withdrawing pulmonary arterial hypertension drug Thelin (sitaxentan) after the company observed life-threathening liver toxicity issues in subjects enrolled in a
Pfizer snags Encysive in $195M buyout
Pfizer has demonstrated once again just how interested it is in biotech with its $195
ALSO NOTED: At GSK, a public race for the top spot; Encysive plans another Phase III;Elixir announces $86M IPO; and much more..
> GlaxoSmithKline is holding a very public race to choose the company's next CEO. GSK's current chief, Jean-Pierre Garnier, announced in September 2005 that he was retiring and that the company
FDA stands firms on need for Thelin trial
The FDA has handed Encysive its fourth--that's right, fourth--dose of bad news for Thelin, a pulmonary arterial hypertension treatment. Encysive received its
